We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+8.51%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$342M
AUM Growth
+$89.9M
Cap. Flow
+$78.3M
Cap. Flow %
22.9%
Top 10 Hldgs %
35.24%
Holding
113
New
44
Increased
16
Reduced
11
Closed
37

Top Buys

Rank Stock Value
1
XRAY icon
Dentsply Sirona
XRAY
+$9.51M
2
DXCM icon
DexCom
DXCM
+$8.48M
3
AGN
Allergan plc
AGN
+$8.14M
4
CNC icon
Centene
CNC
+$6.89M
5
INCY icon
Incyte
INCY
+$6.33M

Top Sells

Rank Stock Value
1
LH icon
Labcorp
LH
+$10M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$8.72M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$6.55M
4
NXTM
NxStage Medical Inc.
NXTM
+$5.56M
5
QGENF
QIAGEN NV
QGENF
+$5.26M

Sector Composition

Rank Sector Weight
1 Healthcare 49.95%
2 Industrials 2.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
76
AbbVie
ABBV
$438B
– –
-46,012
Closed -$3.34M
AGEN
77
CALL
Agenus
AGEN
$291M
– –
-10,190
Closed -$782K
ARAY icon
78
CALL
Accuray
ARAY
$34.9M
– –
-10,500
Closed -$50K
AZN icon
79
CALL
AstraZeneca
AZN
$251B
– –
-100,000
Closed -$6.82M
BRKR icon
80
Bruker
BRKR
$8.58B
– –
-81,617
Closed -$2.35M
CDTX
81
DELISTED
Cidara Therapeutics
CDTX
– –
-7,500
Closed -$1.13M
CRVO icon
82
CervoMed
CRVO
$26.5M
– –
-74
Closed -$193K
EXAS
83
DELISTED
Exact Sciences
EXAS
– –
-125,000
Closed -$4.42M
GILD icon
84
Gilead Sciences
GILD
$165B
– –
-50,000
Closed -$3.54M
LH icon
85
Labcorp
LH
$26.1B
– –
-75,660
Closed -$10M
MRK icon
86
CALL
Merck
MRK
$323B
– –
-104,800
Closed -$6.41M
MRK icon
87
PUT
Merck
MRK
$323B
– –
-136,240
Closed -$8.33M
OCGN icon
88
Ocugen
OCGN
$444M
– –
-225
Closed -$24K
SUPN icon
89
Supernus Pharmaceuticals
SUPN
$2.74B
– –
-80,000
Closed -$3.45M
NUVA
90
CALL
DELISTED
NuVasive, Inc.
NUVA
– –
-50,000
Closed -$3.85M
VIVE
91
DELISTED
VIVEVE MED INC
VIVE
– –
-200
Closed -$1.44M
OTIC
92
DELISTED
Otonomy, Inc.
OTIC
– –
-96,800
Closed -$1.82M
CLVS
93
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-70,000
Closed -$6.55M
CLVS
94
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-30,000
Closed -$2.81M
EPZM
95
DELISTED
Epizyme, Inc
EPZM
– –
-100,000
Closed -$1.51M
XENT
96
CALL
DELISTED
Intersect ENT, Inc
XENT
– –
-4,500
Closed -$126K
ADMS
97
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-79,103
Closed -$1.45M
NEOS
98
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-150,000
Closed -$1.09M
WMGI
99
CALL
DELISTED
Wright Medical Group Inc
WMGI
– –
-100,000
Closed -$2.75M
IMMU
100
DELISTED
Immunomedics Inc
IMMU
– –
-256,800
Closed -$2.27M
1 2 3
4
5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q3 2017 Portfolio in Review

As of Q3 2017, Pura Vida Investments held 113 positions worth $342M, up 36% from $252M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Pura Vida Investments deployed $78.3M of net new capital in Q3 2017, opening 44 new positions and adding to 16 existing holdings. Its largest new stake was Dentsply Sirona: 160,000 shares worth $9.57M.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 66% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Alexion Pharmaceuticals, an estimated $8.72M trimmed.

  • Pura Vida Investments's largest Q3 2017 buy was Dentsply Sirona: 160,000 shares worth $9.57M.
  • Pura Vida Investments added most to Athenahealth, Inc. in Q3 2017, an estimated $2.31M increase.
  • Pura Vida Investments's biggest Q3 2017 reduction was Alexion Pharmaceuticals, cutting an estimated $8.72M.
  • Pura Vida Investments fully exited Labcorp in Q3 2017, selling an estimated $10M.
  • Pura Vida Investments's ten largest holdings make up 35% of its $342M portfolio in Q3 2017.
  • Pura Vida Investments opened 44 new positions and closed 37 in Q3 2017.
  • Pura Vida Investments's portfolio value rose 36% quarter-over-quarter to $342M.

Based on Pura Vida Investments's 13F filing for Q3 2017, filed 14 Nov 2017.